Latest Pozen Inc (POZN) Headlines
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
3 Stocks Under $10 Triggering Breakouts
at The Street - Wed Mar 12, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
POZEN Reports Fourth Quarter & Year End 2013 Results
Business Wire - Wed Mar 05, 6:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013.
POZEN to Present at the Roth Capital Partners 26th Annual Growth Stock Conference
Business Wire - Tue Mar 04, 6:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that John R. Plachetka, Pharm.D., the Company's Chairman, President and Chief Executive Officer, will present at the ROTH Capital Partners 26th Annual Conference on Monday, March 10, 2014 at 12:00 p.m. (PT) at The Ritz Carlton in Dana Point, California. The presentation will be webcast and available for replay on POZEN's home page at www.pozen.com.
POZEN Announces March 5th Webcast of Fourth Quarter and Year End 2013 Results
Business Wire - Wed Feb 26, 6:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release fourth quarter and year end 2013 results on March 5, 2014, before the market opens.
Pozen's Wagon is Tied to Horizon and Sanofi
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 1:30PM CST
Sometimes collaboration deals with big pharmaceutical companies don't work out, and that was the case with Pozen's once-lucrative partnership with AstraZeneca The two teamed up to develop arthritis drug Vimovo in 2006, but sales have been elusive...
Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 7:00AM CST
Avanir Pharmaceuticals had high hopes for AVP-923, a neuropathy pain treatment for Alzheimer's, Parkinson's, and autism. However, AVP-923 failed to do better than placebo in a key mid-stage multiple sclerosis trial, disappointing investors and...
POZEN promotes Dennis McNamara to SVP and chief business officer
M2 - Thu Jan 02, 6:56AM CST
Pharmaceutical company POZEN Inc (NASDAQ
OZN) announced on Thursday that Dennis McNamara has been promoted to senior vice president and chief business officer.
POZEN Announces Appointment of Dennis McNamara to Senior Vice President and Chief Business Officer
Business Wire - Thu Jan 02, 6:29AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the promotion of Dennis McNamara to Senior Vice President and Chief Business Officer. Mr. McNamara is responsible for leading corporate development, alliance management and intellectual property efforts at POZEN. Prior to this appointment, Mr. McNamara held the position of Vice President, Business Development at POZEN, where he has been instrumental in successfully licensing POZEN's products and product candidates to major pharmaceutical companies, including GlaxoSmithKline, AstraZeneca AB, sanofi-aventis U.S. LLC, Horizon Pharma US, Inc., and Cilag GmbH International.
Uptrend Call Working As Pozen Stock Rises 66.0% (POZN)
Comtex SmarTrend(R) - Thu Dec 26, 9:38AM CST
SmarTrend identified an Uptrend for Pozen (NASDAQOZN) on September 5th, 2013 at $5.80. In approximately 4 months, Pozen has returned 66.03% as of today's recent price of $9.63.
POZEN Announces New PA8140/PA32540 PDUFA Date of April 25, 2014
Business Wire - Mon Dec 23, 6:00AM CST
POZEN Inc. (NASDAQOZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that following ongoing interactions with the United States Food & Drug Administration (FDA) concerning its New Drug Application (NDA) for PA8140/PA32540 tablets, the Company has decided to conduct a comparative Phase 1 pharmacokinetic study. The goal of the study is to determine the pharmacokinetic profile of the omeprazole component of PA8140 tablets and compare it to that of PA32540 tablets. Both PA dosage forms contain 40 mg of omeprazole in an immediate release form and are manufactured using nearly identical procedures.
Pozen Up 61.7% Since SmarTrend Uptrend Call (POZN)
Comtex SmarTrend(R) - Thu Dec 19, 9:13AM CST
SmarTrend identified an Uptrend for Pozen (NASDAQOZN) on September 5th, 2013 at $5.80. In approximately 4 months, Pozen has returned 61.72% as of today's recent price of $9.38.
50.7% Return Seen to Date on SmarTrend Pozen Call (POZN)
Comtex SmarTrend(R) - Wed Dec 11, 4:54PM CST
SmarTrend identified an Uptrend for Pozen (NASDAQOZN) on September 5th, 2013 at $5.80. In approximately 3 months, Pozen has returned 50.69% as of today's recent price of $8.74.
POZEN Clarifies Ex-Dividend Date for Previously Announced Special Cash Distribution
Business Wire - Thu Dec 05, 3:20PM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the ex-dividend date for POZEN's previously announced $1.75 special cash distribution is December 31, 2013. On November 21, 2013 POZEN announced that its Board of Directors had declared a special cash distribution of $1.75 per share payable to stockholders of record holding outstanding shares of POZEN's common stock as of the close of business on December 11, 2013, with an expected payment date of December 30, 2013. Because the special cash distribution exceeded 25% of the value of POZEN's common stock at the time of declaration, in accordance with Financial Industry Regulatory Authority Rule 11140, NASDAQ has determined that the ex-dividend date for this special cash distribution will be December 31, 2013, the first business day following the payable date. As a result, shares of POZEN's common stock issued and outstanding on December 11, 2013 shall continue to trade with the right to receive the special cash distribution through the expected payment date of December 30, 2013. Please consult with your broker, legal or financial advisors as to any questions concerning the impact of the December 31, 2013 ex-dividend date.
Shares of POZN Up 34.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 04, 11:06AM CST
SmarTrend identified an Uptrend for Pozen (NASDAQOZN) on September 5th, 2013 at $5.80. In approximately 3 months, Pozen has returned 34.83% as of today's recent price of $7.82.
Healthcare Sector Announces Voluntary Recalls, Scheduled Presentations and Offering Programs - Research Report on Baxter, Incyte, Horizon Pharma, POZEN, and IntelliPharmaCeutics
PR Newswire - Mon Dec 02, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Horizon Pharma, Inc. (NASDAQ: HZNP), POZEN Inc. (NASDAQ: POZN), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
2014 FDA Drug Approval Decision Calendar
at The Street - Wed Nov 27, 7:00AM CST
Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.
Nasdaq stocks posting largest percentage increases
AP - Fri Nov 22, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
3 Stocks Under $10 Triggering Breakouts
at The Street - Wed Mar 12, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
POZEN Reports Fourth Quarter & Year End 2013 Results
Business Wire - Wed Mar 05, 6:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013.
POZEN to Present at the Roth Capital Partners 26th Annual Growth Stock Conference
Business Wire - Tue Mar 04, 6:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that John R. Plachetka, Pharm.D., the Company's Chairman, President and Chief Executive Officer, will present at the ROTH Capital Partners 26th Annual Conference on Monday, March 10, 2014 at 12:00 p.m. (PT) at The Ritz Carlton in Dana Point, California. The presentation will be webcast and available for replay on POZEN's home page at www.pozen.com.
POZEN Announces March 5th Webcast of Fourth Quarter and Year End 2013 Results
Business Wire - Wed Feb 26, 6:30AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release fourth quarter and year end 2013 results on March 5, 2014, before the market opens.
Pozen's Wagon is Tied to Horizon and Sanofi
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 1:30PM CST
Sometimes collaboration deals with big pharmaceutical companies don't work out, and that was the case with Pozen's once-lucrative partnership with AstraZeneca The two teamed up to develop arthritis drug Vimovo in 2006, but sales have been elusive...
Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 7:00AM CST
Avanir Pharmaceuticals had high hopes for AVP-923, a neuropathy pain treatment for Alzheimer's, Parkinson's, and autism. However, AVP-923 failed to do better than placebo in a key mid-stage multiple sclerosis trial, disappointing investors and...
POZEN promotes Dennis McNamara to SVP and chief business officer
M2 - Thu Jan 02, 6:56AM CST
Pharmaceutical company POZEN Inc (NASDAQ
OZN) announced on Thursday that Dennis McNamara has been promoted to senior vice president and chief business officer. POZEN Announces Appointment of Dennis McNamara to Senior Vice President and Chief Business Officer
Business Wire - Thu Jan 02, 6:29AM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the promotion of Dennis McNamara to Senior Vice President and Chief Business Officer. Mr. McNamara is responsible for leading corporate development, alliance management and intellectual property efforts at POZEN. Prior to this appointment, Mr. McNamara held the position of Vice President, Business Development at POZEN, where he has been instrumental in successfully licensing POZEN's products and product candidates to major pharmaceutical companies, including GlaxoSmithKline, AstraZeneca AB, sanofi-aventis U.S. LLC, Horizon Pharma US, Inc., and Cilag GmbH International.
Uptrend Call Working As Pozen Stock Rises 66.0% (POZN)
Comtex SmarTrend(R) - Thu Dec 26, 9:38AM CST
SmarTrend identified an Uptrend for Pozen (NASDAQ
OZN) on September 5th, 2013 at $5.80. In approximately 4 months, Pozen has returned 66.03% as of today's recent price of $9.63. POZEN Announces New PA8140/PA32540 PDUFA Date of April 25, 2014
Business Wire - Mon Dec 23, 6:00AM CST
POZEN Inc. (NASDAQ
OZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that following ongoing interactions with the United States Food & Drug Administration (FDA) concerning its New Drug Application (NDA) for PA8140/PA32540 tablets, the Company has decided to conduct a comparative Phase 1 pharmacokinetic study. The goal of the study is to determine the pharmacokinetic profile of the omeprazole component of PA8140 tablets and compare it to that of PA32540 tablets. Both PA dosage forms contain 40 mg of omeprazole in an immediate release form and are manufactured using nearly identical procedures. Pozen Up 61.7% Since SmarTrend Uptrend Call (POZN)
Comtex SmarTrend(R) - Thu Dec 19, 9:13AM CST
SmarTrend identified an Uptrend for Pozen (NASDAQ
OZN) on September 5th, 2013 at $5.80. In approximately 4 months, Pozen has returned 61.72% as of today's recent price of $9.38. 50.7% Return Seen to Date on SmarTrend Pozen Call (POZN)
Comtex SmarTrend(R) - Wed Dec 11, 4:54PM CST
SmarTrend identified an Uptrend for Pozen (NASDAQ
OZN) on September 5th, 2013 at $5.80. In approximately 3 months, Pozen has returned 50.69% as of today's recent price of $8.74. POZEN Clarifies Ex-Dividend Date for Previously Announced Special Cash Distribution
Business Wire - Thu Dec 05, 3:20PM CST
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the ex-dividend date for POZEN's previously announced $1.75 special cash distribution is December 31, 2013. On November 21, 2013 POZEN announced that its Board of Directors had declared a special cash distribution of $1.75 per share payable to stockholders of record holding outstanding shares of POZEN's common stock as of the close of business on December 11, 2013, with an expected payment date of December 30, 2013. Because the special cash distribution exceeded 25% of the value of POZEN's common stock at the time of declaration, in accordance with Financial Industry Regulatory Authority Rule 11140, NASDAQ has determined that the ex-dividend date for this special cash distribution will be December 31, 2013, the first business day following the payable date. As a result, shares of POZEN's common stock issued and outstanding on December 11, 2013 shall continue to trade with the right to receive the special cash distribution through the expected payment date of December 30, 2013. Please consult with your broker, legal or financial advisors as to any questions concerning the impact of the December 31, 2013 ex-dividend date.
Shares of POZN Up 34.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 04, 11:06AM CST
SmarTrend identified an Uptrend for Pozen (NASDAQ
OZN) on September 5th, 2013 at $5.80. In approximately 3 months, Pozen has returned 34.83% as of today's recent price of $7.82. Healthcare Sector Announces Voluntary Recalls, Scheduled Presentations and Offering Programs - Research Report on Baxter, Incyte, Horizon Pharma, POZEN, and IntelliPharmaCeutics
PR Newswire - Mon Dec 02, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Horizon Pharma, Inc. (NASDAQ: HZNP), POZEN Inc. (NASDAQ: POZN), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
2014 FDA Drug Approval Decision Calendar
at The Street - Wed Nov 27, 7:00AM CST
Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.
Nasdaq stocks posting largest percentage increases
AP - Fri Nov 22, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
